Literature DB >> 17981262

Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid.

Carmine Stolfi1, Daniele Fina, Roberta Caruso, Flavio Caprioli, Massimiliano Sarra, Massimo Claudio Fantini, Angelamaria Rizzo, Francesco Pallone, Giovanni Monteleone.   

Abstract

The cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway may have a pathogenic role in colorectal cancer (CRC). Recent studies suggest that 5-aminosalicylic acid (5-ASA) reduces the risk of inflammatory bowel disease-related CRC, but the mechanism by which 5-ASA interferes with CRC cell growth remains unknown. In this study, we have examined whether the negative effect of 5-ASA on CRC cells is dependent on COX-2/PGE2 axis inhibition. We show that 5-ASA down-regulates both constitutive and TNF-alpha or IL-1beta-induced COX-2 in HT-115 and HT-29 cells. Inhibition of COX-2 by 5-ASA occurs at the RNA and protein level, and is associated with a significant decrease in PGE2 synthesis, arrest of growth and enhanced death of CRC cells. However, exogenous PGE2 does not revert the 5-ASA-mediated CRC cell proliferation block. 5-ASA also inhibits the growth of DLD-1, a COX-deficient CRC cell line, thus suggesting that the anti-proliferative effect of 5-ASA on CRC cells is not strictly dependent on the inhibition of COX-2/PGE2. Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981262     DOI: 10.1016/j.bcp.2007.09.020

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

1.  Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats.

Authors:  Ilan Aroch; Sarah Kraus; Inna Naumov; Ehud Ron; Shiran Shapira; Dina Kazanov; Nis Giladi; Alex Litvak; Shahar Lev-Ari; Aharon Hallak; Iris Dotan; Baruch Shpitz; Nadir Arber
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 2.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

Review 3.  Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines.

Authors:  Wen-Chi L Chang; Terry V Zenser; Harry S Cooper; Margie L Clapper
Journal:  Cancer Lett       Date:  2013-02-13       Impact factor: 8.679

4.  Radiographic and endoscopic regression of metastatic gastric cancer to the colon in the setting of 5-aminosalicylic acid use.

Authors:  Yuval A Patel; Shannon J McCall; Xuefeng Zhang; Tracy Jaffe; Rahul A Shimpi
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 5.  Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.

Authors:  Sigrun Thorsteinsdottir; Thorkell Gudjonsson; Ole Haagen Nielsen; Ben Vainer; Jakob Benedict Seidelin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

6.  Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Authors:  Manisha Bajpai; Darren N Seril; James Van Gurp; Xin Geng; Janet Alvarez; Carlos D Minacapelli; Steve Gorin; Koushik K Das; Elizabeth Poplin; Jerry Cheng; Peter S Amenta; Kiron M Das
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

7.  Early Mechanistic Events Induced by Low Molecular Weight Polycyclic Aromatic Hydrocarbons in Mouse Lung Epithelial Cells: A Role for Eicosanoid Signaling.

Authors:  Katelyn J Siegrist; DeeDee Romo; Brad L Upham; Michael Armstrong; Kevin Quinn; Lauren Vanderlinden; Ross S Osgood; Kalpana Velmurugan; Marc Elie; Jonathan Manke; Dominik Reinhold; Nichole Reisdorph; Laura Saba; Alison K Bauer
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

8.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

Review 9.  Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.

Authors:  Lauren N Cherry; Nancy S Yunker; Erika R Lambert; DaleMarie Vaughan; Denise K Lowe
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

10.  Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.

Authors:  Elizabeth Managlia; Rebecca B Katzman; Jeffrey B Brown; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.